港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

軒竹生物-B

32.360

+1.0203.25%

成交量：357.40萬

成交額：1.23億

市值：167.62億

市盈率：-53.27

高：37.000

開：33.000

低：31.860

收：31.340

52周最高：96.900

52周最低：23.820

股本：5.18億

香港流通股本：1.61億

量比：3.30

換手率：2.22%

股息：- -

股息率：- -

每股收益(LYR):-0.607

淨資產收益率：-21.10%

總資產收益率：-9.60%

市淨率：10.67

市盈率(LYR):-53.27

市銷率: 282.50

資料載入中...

總覽公司新聞資訊公告

四環醫藥：本集團旗下非全資附屬公司軒竹生物被調入滬港通與深港通下港股通標的名單。

軒竹生物-B(02575)獲納入港股通股票名單

海思科1類新藥HSK31679擬納入突破性治療品種；FDA授予Sutacimig突破性療法認定；軒竹生物吡洛西利新適應症獲批上市

軒竹生物-B盤中異動早盤快速跳水5.27%

軒竹生物-B（02575）2026年2月股份變動月報：股本維持不變

國產小分子抗癌藥拿下重磅適應症

3月NMPA批准證明文件：2026年能讓Biotech活下去的，只有這兩種打法

國內外藥企攻堅女性健康，近期新藥突破不斷

國內外藥企共同發力，大批新藥、新適應症同日獲批 / 申報！

軒竹生物-B盤中異動早盤大幅跳水5.08%報57.900港元

軒竹生物-B(02575)：軒悦寧®第三個適應症上市申請獲得NMPA批准，用於一線治療HR+/HER2-晚期乳腺癌

軒竹生物-B：宣愈寧比瑞西利片補充新藥申請獲批新適應症

四環醫藥(00460.HK)附屬軒竹生物獲納入恒生綜合指數成份股

軒竹生物-B(02575)獲納入恒生綜合指數成分股

智通财经网

軒竹生物-B(02575)獲納入恒生綜合指數有望成為港股通標的

軒竹生物－Ｂ(02575)股價下跌5%，現價港幣$64.6

阿斯达克财经

軒竹生物-B盤中異動股價大漲5.05%

軒竹生物-B盤中異動股價大漲5.19%

四環醫藥仿製藥觸底中，軒竹生物成功分拆，創新藥進入收穫期，惠升生物佈局糖尿病全管線也迎

軒竹生物（02575）2026年1月無新增發行或股份變動

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02575/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"軒竹生物-B","latestPrice":32.36,"timestamp":1775808558430,"preClose":31.34,"halted":0,"volume":3574004,"delay":0,"changeRate":0.03254626675175493,"floatShares":160701996,"shares":518000000,"eps":-0.6074398897260381,"marketStatus":"休市中","change":1.02,"latestTime":"04-10 16:09:18","open":33,"high":37,"low":31.86,"amount":122939280,"amplitude":0.164008,"askPrice":32.36,"askSize":500,"bidPrice":32.3,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.6017093247286227,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":31.34,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":3.3031460256643066,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"-9.60%","roe":"-21.10%","lyrEps":-0.60744,"volumeRatio":3.3031460256643066,"shares":518000000,"dividePrice":0,"high":37,"amplitude":0.164008,"preClose":31.34,"low":31.86,"week52Low":23.82,"pbRate":"10.67","psRate":"282.50","week52High":96.9,"institutionHeld":0,"latestPrice":32.36,"committee":0.5,"eps":-0.6074398897260381,"divideRate":0,"volume":3574004,"delay":0,"ttmEps":-0.6017093247286227,"open":33,"prevYearClose":70.5,"prevWeekClose":31.06,"prevMonthClose":29.32,"prevQuarterClose":29.32,"fiveDayClose":29.32,"twentyDayClose":52.9,"sixtyDayClose":59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-04-10","current":-53.779278,"percent":0.068376,"low":-70.039607,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"high":-22.444691,"avg":-50.612793,"sd":9.790471,"marketCap":16760790484},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484}],"updateTime":1775863914695},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618697300","title":"四環醫藥：本集團旗下非全資附屬公司軒竹生物被調入滬港通與深港通下港股通標的名單。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618697300","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618697300?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 07:38","pubTimestamp":1773013120,"startTime":"0","endTime":"0","summary":"来源：滚动播报四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","BK1593","BK1515","00460","02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617066429","title":"軒竹生物-B(02575)獲納入港股通股票名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617066429?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 18:20","pubTimestamp":1772965216,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，根据上海证券交易所及深圳证券交易所于2026年3月6日分别发布的《关于沪港通下港股通标的调整的通知》、《关于深港通下的港股通标的证券名单调整的公告》，本公司被调入沪港通与深港通下港股通标的名单，自2026年3月9日起正式生效。沪港通及深港通是香港与中国内地的资本市场投资者之间的股票交易与投资的渠道。董事会认为，本公司被调入沪港通与深港通下港股通标的名单，将有助于扩大本公司的股东群体并提升本公司股份的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191","VT","BK4588","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617870466","title":"海思科1類新藥HSK31679擬納入突破性治療品種；FDA授予Sutacimig突破性療法認定；軒竹生物吡洛西利新適應症獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617870466","media":"药财社","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617870466?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 18:59","pubTimestamp":1772794763,"startTime":"0","endTime":"0","summary":"此次拟纳入突破性治疗程序，有望加速该药物的研发进程与上市审批。2FDA授予Sutacimig突破性疗法认定Hemab Therapeutics今日宣布，美国食品药品监督管理局已授予其在研创新药物Sutacimig突破性疗法认定，旨在预防Glanzmann血小板无力症患者的出血发作。此前，Sutacimig已先后获得FDA授予的快速通道资格与孤儿药资格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030619064095436413&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030619064095436413&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617687075","title":"軒竹生物-B盤中異動 早盤快速跳水5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687075?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 11:09","pubTimestamp":1772766558,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘11时09分，轩竹生物-B股票出现波动，股价快速跳水5.27%。截至发稿，该股报50.300港元/股，成交量20.65万股，换手率0.13%，振幅6.21%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为2.61%。其相关个股中，药捷安康-B、宜明昂科-B、百奥赛图-B涨幅较大，振幅较大的相关个股有药捷安康-B、百奥赛图-B、映恩生物-B，振幅分别为25.74%、12.13%、11.61%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111409352","title":"軒竹生物-B（02575）2026年2月股份變動月報：股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1111409352","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111409352?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:46","pubTimestamp":1772700417,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年3月5日披露2026年2月股份变动月报。本次月报显示，截至2026年2月28日，公司股本结构保持稳定，未发生新发行、回购或注销等变动。轩竹生物科技股份有限公司目前注册股本合计为517,947,790股。截至月末，轩竹生物科技股份有限公司整体股本水平维持不变。公司表示将继续严格遵守香港联交所《上市规则》及其他相关法律法规的要求，按时披露后续股份变动信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7babad1b4c042890cc8c6c387e110b44","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617597371","title":"國產小分子抗癌藥拿下重磅適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2617597371","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617597371?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 10:16","pubTimestamp":1772676960,"startTime":"0","endTime":"0","summary":"近日，轩竹生物的吡洛西利片获NMPA批准新增适应症，联合芳香化酶抑制剂用于HR+/HER2-晚期乳腺癌初始内分泌治疗，成为国内首个且唯一覆盖该类乳腺癌全疗程的同类药物。吡洛西利是国内首个获批的CDK2/4/6抑制剂，可强效抑制肿瘤细胞增殖，降低血液学毒性，提升治疗耐受性，延缓耐药发生。此前，吡洛西利已获批两项适应症并纳入医保目录，BRIGHT-2和BRIGHT-1研究也分别显示其联合氟维司群及单药治疗具有优异数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305101813a6a47257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305101813a6a47257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617059737","title":"3月NMPA批准證明文件：2026年能讓Biotech活下去的，只有這兩種打法","url":"https://stock-news.laohu8.com/highlight/detail?id=2617059737","media":"药闻天下","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617059737?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:24","pubTimestamp":1772616262,"startTime":"0","endTime":"0","summary":"而手术不仅带来创伤，还可能导致早产、流产等不可逆的生育力损害。希维她的获批，直接重塑了这一临床路径。逆转病程：近60%的患者在首次治疗后6个月，病理结果转为正常或低级别病变，成功免除了手术之苦。深层清毒：治疗12个月时，约60%的基线HPV被成功清除。结合近期行业动态，这款药物在2月末刚刚同日斩获两项新适应症。一个靶点，吃透了整个2型炎症版图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182420a6a1c279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304182420a6a1c279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617568772","title":"國內外藥企攻堅女性健康，近期新藥突破不斷","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568772","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568772?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 16:26","pubTimestamp":1772612760,"startTime":"0","endTime":"0","summary":"女性健康领域正成医药创新核心，2026年以来国内外药企新药/新适应症突破不断。亚虹医药核心产品希维她®获批上市，用于治疗子宫颈上皮内瘤变2级，是非手术无创治疗产品，旨在重塑全球治疗标准；轩竹生物自主研发的轩悦宁®第三个适应症获批，成为中国首个覆盖HR+/HER2-晚期乳腺癌全疗程的CDK4/6抑制剂；石药集团注射用紫杉醇白蛋白纳米粒获FDA批准在美国开展临床试验；百利天恒的iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验期中分析达主要终点，多项适应症被纳入突破性治疗品种名单；默沙东PD-1抑制剂可瑞达®获NMPA批准，用于治疗特定类型子宫内膜癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163918a6a156b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163918a6a156b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0208291251.USD","LU0965509283.SGD","LU1571399168.USD","LU0265550946.USD","LU0098860793.USD","LU1989772923.USD","LU2023250843.SGD","IE0009355771.USD","LU1430594728.SGD","LU2360032135.SGD","LU1989772840.SGD","LU0234572021.USD","MRK","IE00BN8TJ469.HKD","LU0868494617.USD","LU1093756325.SGD","SG9999014559.SGD","LU1023059063.AUD","IE00BSNM7G36.USD","SG9999001440.SGD","LU0965508806.USD","LU0265550359.USD","BK4534","LU0942090050.USD","LU1162221912.USD","LU1066053197.SGD","LU1116320737.USD","LU2361044949.HKD","LU2112291526.USD","LU1201861249.SGD","01093","LU0238689110.USD","LU1069347547.HKD","LU0106261372.USD","LU1941712264.USD","LU0320765489.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU0965509101.SGD","LU1934455277.USD","LU2125154778.USD","LU0648001328.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999015341.SGD","LU2324357040.USD","LU0203347892.USD","SGXZ57979304.SGD","LU1917777945.USD","IE000M9KFDE8.USD","BK4516","BK4533","SG9999001176.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU0130102774.USD","LU1037948897.HKD","LU1066051811.HKD","SG9999014575.USD","IE00BFTCPJ56.SGD","BK4550","IE0002141913.USD","SG9999002232.USD","LU0868494708.USD","SG9999015358.SGD","BK4007","LU2125154935.USD","LU0130517989.USD","SG9999013999.USD","LU1066051225.USD","LU0070302665.USD","BK4585","IE00BBT3K403.USD","LU0122379950.USD","LU1934455863.HKD","LU1093756168.USD","SG9999014567.USD","SG9999001176.SGD","IE00BLSP4452.SGD","LU1989771016.USD","LU0266013472.USD","LU1116320901.HKD","IE00BJJMRZ35.SGD","LU0980610538.SGD","LU0203345920.USD","LU0320765646.SGD","BK4559","LU0965509010.AUD","LU1934455194.USD","LU0006306889.USD","LU1699723380.USD","LU0432979614.USD","LU1974910355.USD","LU0477156953.USD","LU1037948541.HKD","LU2023250504.SGD","LU0211331839.USD","LU2461242641.AUD","LU2468319806.SGD","IE00BLSP4239.USD","IE00B4R5TH58.HKD","LU0985320562.USD","IE00B1BXHZ80.USD","LU2361045086.USD","LU2106854487.HKD","LU0861579265.USD","LU1941712348.USD","LU1585245621.USD","02575","LU1066051498.USD","LU2361044865.SGD","LU1035773651.USD","LU1061106388.HKD","LU1291159041.SGD","LU1929549753.HKD","LU2089984988.USD","LU0058720904.USD","BK4588","SG9999014542.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616812581","title":"國內外藥企共同發力，大批新藥、新適應症同日獲批 / 申報！","url":"https://stock-news.laohu8.com/highlight/detail?id=2616812581","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616812581?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 14:33","pubTimestamp":1772606026,"startTime":"0","endTime":"0","summary":"2026年以来，国内已有多款1 类创新药、全球首创产品、新适应症获批上市，同时有多个重磅品种申报上市获受理，覆盖肿瘤、自身免疫、妇科、代谢等核心赛道。如在3月3日，诺和诺德、礼来、亚虹医药等多家药企就相继宣布新药/新适应症在国内申报上市，或获得了《药品注册证书》。截至目前，司美格鲁肽在中国已获批4项适应症。这是吡洛西利继联合氟维司群、单药治疗适应症获批后，在中国获批的第三个适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304143745a449f534&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304143745a449f534&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDE","LU1223082519.USD","02575","BK4132","LU1223083913.SGD","NVO","AD","BK4017","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616583635","title":"軒竹生物-B盤中異動 早盤大幅跳水5.08%報57.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616583635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616583635?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:40","pubTimestamp":1772588402,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时40分，轩竹生物-B股票出现波动，股价急速跳水5.08%。截至发稿，该股报57.900港元/股，成交量2.7万股，换手率0.02%，振幅4.26%。轩竹生物-B股票所在的生物技术行业中，整体跌幅为0.75%。其相关个股中，和誉-B、晶泰控股、三叶草生物-B涨幅较大，振幅较大的相关个股有帝王国际投资、康诺亚-B、晶泰控股，振幅分别为10.09%、8.15%、6.39%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616317315","title":"軒竹生物-B(02575)：軒悦寧®第三個適應症上市申請獲得NMPA批准，用於一線治療HR+/HER2-晚期乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317315","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616317315?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:41","pubTimestamp":1772527312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本公司自主研发的创新药吡洛西利片联合芳香化酶抑制剂一线治疗HR+/HER2-晚期乳腺癌的新适应症上市申请，已获得中国国家药品监督管理局批准上市。HR+/HER2-乳腺癌是中国最高发的亚型，占病例总数约75%，HR+/HER2 乳腺癌患者中约有30%被诊断为晚期乳腺癌。BRIGHT-3 研究是一项在中国58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4203","BK4225","BK1191","HR","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171371156","title":"軒竹生物-B：宣愈寧比瑞西利片補充新藥申請獲批新適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=1171371156","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171371156?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:40","pubTimestamp":1772527222,"startTime":"0","endTime":"0","summary":"轩竹生物-B（股票代码：02575）近日宣布，其核心产品宣愈宁比瑞西利片（Xuanyuening Bireociclib Tablets）的补充新药申请已获得监管机构批准，新增一项重要适应症。此次获批标志着该药物在临床应用范围的进一步拓展，有望为特定患者群体提供新的治疗选择。\n比瑞西利片作为轩竹生物研发的创新药物，此次新适应症的获批将强化其在相关治疗领域的市场竞争力。公司表示，将积极推进该药物的商业化进程，以满足未竟的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613227810","title":"四環醫藥(00460.HK)附屬軒竹生物獲納入恒生綜合指數成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613227810","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613227810?lang=zh_tw&edition=fundamental","pubTime":"2026-02-22 18:37","pubTimestamp":1771756621,"startTime":"0","endTime":"0","summary":"格隆汇2月22日丨四环医药公告，根据恒生指数有限公司于2026年2月13日公布的截至2025年12月31日止期间恒生指数系列季度检讨结果，集团旗下非全资附属公司轩竹生物科技股份有限公司被纳入恒生综合指数成分股，该调整将于2026年3月9日正式生效。　　恒生综合指数作为港股综合性基准指标，全面覆盖在香港联交所主板上市、累计市值位列前95%的上市企业。获纳入恒生综合指数成分股，轩竹生物股份预计将符合沪港通及深港通交易的纳入标准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260222/32021373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1600","HSCI","BK1191","BK1593","00460","BK1515","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613221082","title":"軒竹生物-B(02575)獲納入恒生綜合指數成分股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613221082","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613221082?lang=zh_tw&edition=fundamental","pubTime":"2026-02-22 18:07","pubTimestamp":1771754870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，根据恒生指数有限公司于2026年2月13日公布的截至2025年12月31日止期间的恒生指数系列季度检讨结果，公司被纳入恒生综合指数的成分股，该调整将于2026年3月9日正式生效。获纳入恒生综合指数成分股，公司股份预计将符合沪港通及深港通交易的纳入标准。董事会认为，公司获纳入恒生综合指数成份股，反映投资者对公司价值与成长潜力的认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","02575","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611425156","title":"軒竹生物-B(02575)獲納入恒生綜合指數 有望成為港股通標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2611425156","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611425156?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 19:26","pubTimestamp":1770982006,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中轩竹生物-B(02575)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，轩竹生物有可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。2025年12月7日，国家医疗保障局公布2025年国家医保药品目录调整结果，轩竹生物自主研发的1类创新药、CDK4/6抑制剂吡洛西利片成功纳入目录，为晚期乳腺癌患者带来医保报销新福利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","02575","BK1191","HSCI","VT","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610913362","title":"軒竹生物－Ｂ(02575)股價下跌5%，現價港幣$64.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2610913362","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610913362?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 13:35","pubTimestamp":1770874500,"startTime":"0","endTime":"0","summary":"[下跌股]轩竹生物－Ｂ(02575) 股价在下午01:35比前收市价下跌5%，现股价为港币$64.6。至目前为止，今日最高价为$68.5，而最低价为$64.6。总成交量为35.25万股，总成交金额为港币$2.324千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602122907/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602122907/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610681325","title":"軒竹生物-B盤中異動 股價大漲5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610681325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610681325?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 10:24","pubTimestamp":1770603859,"startTime":"0","endTime":"0","summary":"2026年02月09日早盘10时24分，轩竹生物-B股票出现波动，股价快速拉升5.05%。截至发稿，该股报72.800港元/股，成交量4.4万股，换手率0.03%，振幅5.48%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为1.77%。其相关个股中，歌礼制药-B、北海康成-B、中国抗体-B涨幅较大，振幅较大的相关个股有北海康成-B、奥星生命科技、旺山旺水-B，振幅分别为10.03%、8.75%、8.34%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102419a6e400de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102419a6e400de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609510330","title":"軒竹生物-B盤中異動 股價大漲5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609510330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609510330?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 14:07","pubTimestamp":1770358072,"startTime":"0","endTime":"0","summary":"2026年02月06日下午盘14时07分，轩竹生物-B股票出现波动，股价急速拉升5.19%。截至发稿，该股报69.950港元/股，成交量28.9605万股，换手率0.18%，振幅7.44%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为0.70%。其相关个股中，歌礼制药-B、诺诚健华、亿腾嘉和涨幅较大，振幅较大的相关个股有歌礼制药-B、创胜集团-B、诺诚健华，振幅分别为17.31%、13.75%、13.51%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206140752a6da37ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206140752a6da37ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609514892","title":"四環醫藥仿製藥觸底中，軒竹生物成功分拆，創新藥進入收穫期，惠升生物佈局糖尿病全管線也迎","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514892","media":"第一上海","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609514892?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 13:14","pubTimestamp":1770354864,"startTime":"0","endTime":"0","summary":"公司正处于从传统仿制药向“医美+创新药”双轮驱动的战略转型期。预计到2028年，医美板块收入将达到40亿元左右，复合增速超过50%。考虑到公司全面领先的医美管线布局及其未来的盈利能力，建议投资者重点关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206133039a4832565&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206133039a4832565&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1161","00460","BK1593","06978","BK1191","BK1574","BK1515","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177899849","title":"軒竹生物（02575）2026年1月無新增發行或股份變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1177899849","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177899849?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 17:27","pubTimestamp":1770283639,"startTime":"0","endTime":"0","summary":"2026年2月5日，轩竹生物科技股份有限公司（港交所股票代码：02575）发布2026年1月股份变动月报，披露截至1月31日的股本情况。公告显示，该公司注册股本仍包括160,701,996股H股及357,245,794股未上市股份，总计517,947,790股，与上期保持一致。\n报告期内未发生新增发行、购回或注销，H股及未上市股份数量无变化，公共持股量维持上市规则要求的24.96%。同时，公告未披露任何股份期权、可换股票据及其他股权激励计划的变动信息。\n截至2026年1月31日，轩竹生物股本维持稳定。公司确认遵守香港联交所相关上市规则及法律规定，公告由联席公司秘书何成明签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":130,"code":"91000000","status":"200"}]}}